\-\ Texto\\:\\ \ \(0\)\
\-\ alpha\\ fetoprotein\\-\ \(0\)\
\-\ \\ \\ \\ \\ 08\\ oct\\ 2003\\:\\ 13\\ ng\\/ml\\ \\(nl\\ 0\\-15\\ ng\\/ml\\)\ \(0\)\
\-\ \\ \\ \\ \\ 12\\ feb\\ 2004\\:\\ 286\\ ng\\/ml\ \(0\)\
\-\ \\ \\ \\ \\ 06\\ apr\\ 2004\\:\\ 1197\\ ng\\/ml\ \(0\)\
\-\ patient\\ has\\ had\\ close\\ clinical\\ and\\ laboratory\\ follow\\ to\\ evaluate\\ for\\ complications\\.\\ \\ patient\\ is\\ scheduled\\ in\\ june\\ for\\ follow\\ up\\ mr\\ to\\ evaluate\\ for\\ tumor\\ response\\ \\(decrease\\ size\\ and\\/or\\ enhancement\\ pattern\\)\\.\ \(0\)\
\-\ depending\\ upon\\ the\\ response\\,\\ she\\ may\\ have\\ the\\ left\\ lobe\\ lesion\\ treated\\.\ \(0\)\
\-\ ct\\ abdomen\\ 05\\ apr\\ 2004\\:\\ \\ liver\\ demonstrates\\ a\\ nodular\\ contour\\ consistent\\ with\\ chronic\\ cirrhosis\\.\\ \\ there\\ are\\ areas\\ of\\ heterogeneous\\ density\\,\\ throughout\\ the\\ right\\ lobe\\ of\\ the\\ liver\\,\\ without\\ definitive\\ circumscribed\\ mass\\ identified\\.\\ \\ hypertrophy\\ of\\ the\\ caudate\\ lobe\\.\\ \\ the\\ left\\ lobe\\ appears\\ clear\\ by\\ ct\\.\\ small\\ spenule\\ is\\ present\\.\\ atherosclerotic\\ vascular\\ calcification\\ of\\ the\\ abdominal\\ aorta\\ without\\ aneurysmal\\ dilatation\\.\\ degenerative\\ changes\\ of\\ the\\ spine\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ mr\\ abdomen\\ 10\\ apr\\ 2004\\:\\ \\ the\\ liver\\ is\\ diffusely\\ nodular\\ consistent\\ with\\ cirrhosis\\.\\ \\ multiple\\ hyperenhancing\\ lesions\\ seen\\ throughout\\ the\\ right\\ lobe\\ of\\ the\\ liver\\ which\\ appear\\ to\\ conglomerate\\ to\\ a\\ mass\\ in\\ the\\ superior\\ portion\\ of\\ right\\ lobe\\ measuring\\ approximately\\ 13\\ x\\ 10\\ cm\\.\\ \\ a\\ separate\\ conglomeration\\ mass\\ is\\ seen\\ in\\ the\\ inferior\\ portion\\ of\\ right\\ lobe\\ near\\ the\\ tip\\ measuring\\ approximately\\ 7\\ x\\ 7\\ cm\\.\\ \\ \\ additionally\\ there\\ is\\ a\\ hyperenhancing\\ mass\\ measuring\\ approximately\\ 3\\ x\\ 2\\ cm\\ in\\ the\\ left\\ lobe\\ of\\ the\\ liver\\ not\\ seen\\ on\\ the\\ ct\\.\ \(0\)\
\-\ angiography\\ and\\ chemoembolization\\ 16\\ apr\\ 2004\\:\\ \\ the\\ injection\\ of\\ the\\ right\\ hepatic\\ artery\\ initially\\ shows\\ two\\ areas\\ in\\ the\\ right\\ lobe\\ \\(superior\\ and\\ inferior\\)\\ of\\ the\\ liver\\ with\\ increased\\ arterial\\ size\\,\\ neovascualrity\\,\\ tumor\\ staining\\ and\\ puddling\\ of\\ contrast\\ material\\.\\ \\ on\\ a\\ subsequent\\ injection\\ \\(image\\ from\\ later\\ in\\ the\\ run\\)\\,\\ there\\ is\\ early\\ opacification\\ of\\ a\\ portal\\ vein\\ branch\\ in\\ the\\ area\\ indicating\\ a\\ fistulous\\ communication\\ with\\ the\\ proximal\\ right\\ hepatic\\ artery\\ \\(also\\ notice\\ the\\ increasing\\ tumor\\ stain\\ and\\ puddling\\ on\\ this\\ later\\ injection\\)\\.\\ \\ \\ subselected\\ injection\\ of\\ the\\ inferior\\ branch\\ of\\ the\\ right\\ hepatic\\ artery\\.\\ \\ image\\ taken\\ during\\ the\\ infusion\\ of\\ the\\ chemotherapeutic\\-ethiodol\\-contrast\\ mixture\\ into\\ that\\ lower\\ liver\\ lesion\\.\\ \\ notice\\ the\\ dense\\ material\\ present\\ in\\ the\\ upper\\ liver\\ lesion\\,\\ representing\\ chemotherapeutic\\-ethiodol\\-contrast\\ mixture\\ from\\ the\\ prior\\ infusion\\ of\\ that\\ upper\\ lesion\\.\\ \\ \\(due\\ to\\ technical\\ malfunction\\,\\ images\\ of\\ that\\ infusion\\ were\\ unavailable\\)\\ \\ the\\ gelfoam\\ embolization\\ images\\ were\\ not\\ included\\.\ \(0\)\
\-\ non\\ contrast\\ ct\\ \\(post\\ procedure\\)\\ 16\\ apr\\ 2004\\:\\ \\ \\ immediately\\ post\\ chemoembolization\\ \\ this\\ non\\-contrast\\ ct\\ shows\\ hyperedense\\ material\\ \\(ethiodol\\-chemotherapuetic\\-\\ contrast\\ mixture\\ and\\ gelfoam\\-contrast\\ mixture\\)\\ within\\ two\\ masses\\ in\\ the\\ right\\ lobe\\ of\\ the\\ liver\\.\ \(0\)\
\-\ hepatic\\ artery\\ chemoembolization\\ of\\ hcc\\.\ \(0\)\
\-\ hepatocellular\\ carcinoma\\.\ \(6\)\
\-\ metastatic\\ disease\\.\ \(69\)\
\-\ 59\\ year\\ old\\ african\\ american\\ female\\ referred\\ to\\ the\\ interventional\\ radiology\\ department\\ for\\ palliative\\ chemoembolization\\ of\\ a\\ hepatocellular\\ carcinoma\\.\ \(0\)\
\-\ this\\ 59\\ year\\ old\\ african\\ american\\ female\\ has\\ had\\ hepatitis\\ c\\ infection\\ since\\ 2001\\.\\ \\ follow\\ up\\ alpha\\-fetoprotein\\ levels\\ became\\ elevated\\ in\\ febuary\\ 2004\\,\\ after\\ being\\ stable\\ for\\ years\\.\\ \\ ct\\ showed\\ heterogeneous\\ density\\,\\ without\\ obvious\\ mass\\,\\ in\\ the\\ right\\ lobe\\ of\\ the\\ liver\\.\\ \\(although\\ it\\ was\\ not\\ three\\ phase\\ liver\\ protocol\\,\\ only\\ standard\\ ct\\ with\\ contrast\\)\\.\\ \\ \\ mr\\ evaluation\\ demonstated\\ multifocal\\ hyperenhancing\\ lesions\\ in\\ the\\ right\\ lobe\\ of\\ the\\ liver\\,\\ in\\ the\\ region\\ of\\ heterogeneity\\ on\\ ct\\ scan\\.\\ \\ additionally\\,\\ a\\ hyperenhancing\\ lesion\\ was\\ seen\\ in\\ the\\ left\\ lobe\\,\\ that\\ was\\ not\\ appretiated\\ on\\ the\\ ct\\ \\(even\\ in\\ retrospect\\ not\\ visible\\)\\.\\ \\ because\\ of\\ the\\ multifocal\\ nature\\ she\\ is\\ a\\ not\\ a\\ surgical\\ candidate\\ for\\ either\\ resection\\ or\\ transplant\\.\\ \\ radiation\\ oncology\\ determined\\ that\\ because\\ she\\ was\\ asymptomatic\\ and\\ her\\ lesions\\ were\\ larger\\ than\\ 7\\ cm\\,\\ none\\ of\\ their\\ protocols\\ were\\ appropriate\\.\\ \\ she\\ was\\ then\\ referred\\ to\\ interventional\\ radiology\\ for\\ palliative\\ treatment\\ with\\ hepatic\\ artery\\ chemoembolization\\.\ \(0\)\
\-\ in\\ this\\ case\\,\\ during\\ the\\ initial\\ hepatic\\ arteriogram\\,\\ a\\ small\\ arterioportal\\ fistula\\ was\\ identified\\ in\\ the\\ proximal\\ right\\ hepatic\\ artery\\.\\ \\ this\\ precluded\\ the\\ use\\ of\\ the\\ standard\\ protocol\\ to\\ infuse\\ the\\ chemotherapy\\-ethiodol\\ mixture\\ into\\ this\\ vessel\\ \\(do\\ not\\ want\\ this\\ mixture\\ getting\\ into\\ the\\ portal\\ circulation\\)\\ \\ instead\\ the\\ superior\\ and\\ inferior\\ branches\\ of\\ the\\ right\\ hepatic\\ artery\\ were\\ selectively\\ accessed\\ and\\ half\\ the\\ mixture\\ was\\ infused\\ into\\ each\\.\\ \\ then\\ the\\ catheter\\ was\\ withdrawn\\ to\\ embolize\\ the\\ entire\\ right\\ hepatic\\ artery\\.\\ \\ this\\ was\\ done\\ to\\ both\\,\\ cut\\ off\\ blood\\ supply\\ to\\ the\\ liver\\ tumors\\ \\(per\\ protocol\\)\\ and\\ attempt\\ to\\ close\\ the\\ aterioportal\\ fistula\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ mixture\\:\\ 0\\.053392533490023\ \(0\)\
\-\ chemoembolization\\:\\ 0\\.050569502852545134\ \(0\)\
\-\ liver\\:\\ 0\\.05019774526975807\ \(0\)\
\-\ hyperenhancing\\:\\ 0\\.04258123849754419\ \(0\)\
\-\ 2004\\:\\ 0\\.04216523595220543\ \(0\)\
\-\ hepatic\\:\\ 0\\.04209233180374064\ \(0\)\
\-\ apr\\:\\ 0\\.0409604788106485\ \(0\)\
\-\ lobe\\:\\ 0\\.03917592335911657\ \(0\)\
\-\ ng\\/ml\\:\\ 0\\.029777322191545733\ \(0\)\
\-\ artery\\:\\ 0\\.026679213547661326\ \(0\)\
\-\ chemotherapeutic\\-ethiodol\\-contrast\\:\\ 0\\.0231075188046304\ \(0\)\
\-\ infusion\\:\\ 0\\.022005147833938258\ \(0\)\
\-\ injection\\:\\ 0\\.02090277686324612\ \(0\)\
\-\ puddling\\:\\ 0\\.020227801141018055\ \(0\)\
\-\ protocol\\:\\ 0\\.018070815408088036\ \(0\)\
\-\ right\\:\\ 0\\.0165437010845948\ \(0\)\
\-\ inferior\\:\\ 0\\.015199561527439386\ \(0\)\
\-\ material\\:\\ 0\\.015012999279956944\ \(0\)\
\-\ notice\\:\\ 0\\.014888661095772866\ \(0\)\
\-\ ct\\:\\ 0\\.014099256724152538\ \(0\)\
\-\ palliative\\:\\ 0\\.013642465298354584\ \(0\)\
\-\ interventional\\:\\ 0\\.01343811001271969\ \(0\)\
\-\ measuring\\:\\ 0\\.013436523155106468\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.013188279921489481\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.012906154982584198\ \(0\)\
\-\ 7\\:\\ 0\\.01287387239374078\ \(0\)\
\-\ were\\:\\ 0\\.012714851485517176\ \(0\)\
\-\ she\\:\\ 0\\.012575549889668006\ \(0\)\
\-\ branch\\:\\ 0\\.012125461813735444\ \(0\)\
\-\ 59\\:\\ 0\\.012047210272058692\ \(0\)\
\-\ multifocal\\:\\ 0\\.012047210272058692\ \(0\)\
\-\ cm\\:\\ 0\\.012015497341111328\ \(0\)\
\-\ portal\\:\\ 0\\.011790380892346497\ \(0\)\
\-\ african\\:\\ 0\\.011687574304788746\ \(0\)\
\-\ was\\:\\ 0\\.011657270904224352\ \(0\)\
\-\ fetoprotein\\-\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ 1197\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ spenule\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ neovascualrity\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ gelfoam\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ hyperedense\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ ethiodol\\-chemotherapuetic\\-\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ gelfoam\\-contrast\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ febuary\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ chemotherapy\\-ethiodol\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ aterioportal\\:\\ 0\\.0115537594023152\ \(0\)\
\-\ standard\\:\\ 0\\.011462299259439533\ \(0\)\
\-\ lesion\\:\\ 0\\.011405997549151078\ \(0\)\
\-\ \\(\\:\\ 0\\.011360865943546954\ \(0\)\
\-\ not\\:\\ 0\\.011328611667357207\ \(0\)\
\-\ response\\:\\ 0\\.011226524065041264\ \(0\)\
\-\ \\)\\:\\ 0\\.011222086900864561\ \(0\)\
\-\ x\\:\\ 0\\.011084140243830184\ \(0\)\
\-\ fistula\\:\\ 0\\.010984392164304657\ \(0\)\
\-\ close\\:\\ 0\\.010933492856684471\ \(0\)\
\-\ superior\\:\\ 0\\.010729005361943085\ \(0\)\
\-\ follow\\:\\ 0\\.01067575152796763\ \(0\)\
\-\ mr\\:\\ 0\\.01067575152796763\ \(0\)\
\-\ american\\:\\ 0\\.010669950971437086\ \(0\)\
\-\ into\\:\\ 0\\.010659640199002396\ \(0\)\
\-\ appretiated\\:\\ 0\\.010645309624386047\ \(0\)\
\-\ arterioportal\\:\\ 0\\.010645309624386047\ \(0\)\
\-\ precluded\\:\\ 0\\.010645309624386047\ \(0\)\
\-\ approximately\\:\\ 0\\.010395089750546196\ \(0\)\
\-\ \\:\\:\\ 0\\.010369493724685002\ \(0\)\
\-\ the\\:\\ 0\\.010327928215080827\ \(0\)\
\-\ 16\\:\\ 0\\.010135671123429436\ \(0\)\
\-\ 13\\:\\ 0\\.010117146438703113\ \(0\)\
\-\ 06\\:\\ 0\\.010113900570509027\ \(0\)\
\-\ conglomerate\\:\\ 0\\.010113900570509027\ \(0\)\
\-\ subselected\\:\\ 0\\.010113900570509027\ \(0\)\
\-\ infuse\\:\\ 0\\.010113900570509027\ \(0\)\
\-\ infused\\:\\ 0\\.010113900570509027\ \(0\)\
\-\ this\\:\\ 0\\.01007745439909969\ \(0\)\
\-\ contrast\\:\\ 0\\.010027657597944458\ \(0\)\
\-\ 286\\:\\ 0\\.009736859846456891\ \(0\)\
\-\ malfunction\\:\\ 0\\.009736859846456891\ \(0\)\
\-\ selectively\\:\\ 0\\.009736859846456891\ \(0\)\
\-\ embolize\\:\\ 0\\.009736859846456891\ \(0\)\
\-\ additionally\\:\\ 0\\.00970781293737865\ \(0\)\
\-\ that\\:\\ 0\\.009672219715326495\ \(0\)\
\-\ radiology\\:\\ 0\\.009466610057377988\ \(0\)\
\-\ 08\\:\\ 0\\.00944440434014731\ \(0\)\
\-\ 05\\:\\ 0\\.00944440434014731\ \(0\)\
\-\ conglomeration\\:\\ 0\\.00944440434014731\ \(0\)\
\-\ nodular\\:\\ 0\\.009395569612351013\ \(0\)\
\-\ in\\:\\ 0\\.009388929111906074\ \(0\)\
\-\ 0\\-15\\:\\ 0\\.009205450792579874\ \(0\)\
\-\ demonstated\\:\\ 0\\.009205450792579874\ \(0\)\
\-\ evaluate\\:\\ 0\\.009054328330949078\ \(0\)\
\-\ protocols\\:\\ 0\\.00900341844680365\ \(0\)\
\-\ want\\:\\ 0\\.00900341844680365\ \(0\)\
\-\ withdrawn\\:\\ 0\\.00900341844680365\ \(0\)\
\-\ lesions\\:\\ 0\\.008994340129792716\ \(0\)\
\-\ seen\\:\\ 0\\.008852569410577668\ \(0\)\
\-\ fistulous\\:\\ 0\\.008828410068527736\ \(0\)\
\-\ arteriogram\\:\\ 0\\.008535954562218156\ \(0\)\
\-\ referred\\:\\ 0\\.008452244936974159\ \(0\)\
\-\ retrospect\\:\\ 0\\.00841103951660305\ \(0\)\
\-\ throughout\\:\\ 0\\.00838465878453454\ \(0\)\
\-\ 2001\\.\\:\\ 0\\.008297001014650718\ \(0\)\
\-\ alpha\\-fetoprotein\\:\\ 0\\.008297001014650718\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.008236422429344706\ \(0\)\
\-\ technical\\:\\ 0\\.0081920957621297\ \(0\)\
\-\ portion\\:\\ 0\\.008113254645764316\ \(0\)\
\-\ heterogeneity\\:\\ 0\\.008094968668874495\ \(0\)\
\-\ later\\:\\ 0\\.00808759801046638\ \(0\)\
\-\ run\\:\\ 0\\.008004545508341137\ \(0\)\
\-\ identified\\:\\ 0\\.00800384545527214\ \(0\)\
\-\ then\\:\\ 0\\.007971079628891454\ \(0\)\
\-\ without\\:\\ 0\\.00791092988083156\ \(0\)\
\-\ because\\:\\ 0\\.007836221013331712\ \(0\)\
\-\ tumor\\:\\ 0\\.007833154527958628\ \(0\)\
\-\ mass\\:\\ 0\\.007788079993103306\ \(0\)\
\-\ 10\\:\\ 0\\.007550784346911954\ \(0\)\
\-\ areas\\:\\ 0\\.007536951956084055\ \(0\)\
\-\ size\\:\\ 0\\.007509504250009886\ \(0\)\
\-\ alpha\\:\\ 0\\.007502589738673896\ \(0\)\
\-\ caudate\\:\\ 0\\.007502589738673896\ \(0\)\
\-\ oct\\:\\ 0\\.007444330547886433\ \(0\)\
\-\ feb\\:\\ 0\\.007444330547886433\ \(0\)\
\-\ staining\\:\\ 0\\.007444330547886433\ \(0\)\
\-\ hcc\\:\\ 0\\.007388551236721563\ \(0\)\
\-\ density\\:\\ 0\\.00736993802584524\ \(0\)\
\-\ june\\:\\ 0\\.00733504927797942\ \(0\)\
\-\ getting\\:\\ 0\\.007234182906896683\ \(0\)\
\-\ cut\\:\\ 0\\.007234182906896683\ \(0\)\
\-\ accessed\\:\\ 0\\.0071865188909453395\ \(0\)\
\-\ oncology\\:\\ 0\\.0071405276461075015\ \(0\)\
\-\ post\\:\\ 0\\.0070533028389837315\ \(0\)\
\-\ instead\\:\\ 0\\.007053120864326805\ \(0\)\
\-\ nl\\:\\ 0\\.0070115105126694255\ \(0\)\
\-\ unavailable\\:\\ 0\\.0070115105126694255\ \(0\)\
\-\ image\\:\\ 0\\.006996564000780081\ \(0\)\
\-\ stain\\:\\ 0\\.00689406338463576\ \(0\)\
\-\ candidate\\:\\ 0\\.00689406338463576\ \(0\)\
\-\ during\\:\\ 0\\.006854545871359917\ \(0\)\
\-\ circulation\\:\\ 0\\.006821232649177292\ \(0\)\
\-\ \\,\\:\\ 0\\.006741141867402962\ \(0\)\
\-\ proximal\\:\\ 0\\.006724883831473172\ \(0\)\
\-\ atherosclerotic\\:\\ 0\\.006719055006359845\ \(0\)\
\-\ to\\:\\ 0\\.006716667498448014\ \(0\)\
\-\ for\\:\\ 0\\.0066890655838781204\ \(0\)\
\-\ abdomen\\:\\ 0\\.006635345381115849\ \(0\)\
\-\ communication\\:\\ 0\\.006564686676534965\ \(0\)\
\-\ hepatitis\\:\\ 0\\.006426599500050265\ \(0\)\
\-\ attempt\\:\\ 0\\.006426599500050265\ \(0\)\
\-\ two\\:\\ 0\\.006415022903318495\ \(0\)\
\-\ carcinoma\\:\\ 0\\.006348434259543556\ \(0\)\
\-\ a\\:\\ 0\\.006237480500423611\ \(0\)\
\-\ supply\\:\\ 0\\.006232077868178348\ \(0\)\
\-\ separate\\:\\ 0\\.006209673630485949\ \(0\)\
\-\ transplant\\:\\ 0\\.006187645952482828\ \(0\)\
\-\ shows\\:\\ 0\\.0061582534724217005\ \(0\)\
\-\ branches\\:\\ 0\\.006123700783191305\ \(0\)\
\-\ aneurysmal\\:\\ 0\\.0060827406999618095\ \(0\)\
\-\ became\\:\\ 0\\.00604302202434539\ \(0\)\
\-\ up\\:\\ 0\\.006023190435266641\ \(0\)\
\-\ opacification\\:\\ 0\\.005930614656380219\ \(0\)\
\-\ half\\:\\ 0\\.005912782871248136\ \(0\)\
\-\ determined\\:\\ 0\\.005843787152394373\ \(0\)\
\-\ depending\\:\\ 0\\.005827091181519629\ \(0\)\
\-\ each\\:\\ 0\\.00579432407509051\ \(0\)\
\-\ indicating\\:\\ 0\\.005778242695546848\ \(0\)\
\-\ representing\\:\\ 0\\.005778242695546848\ \(0\)\
\-\ hypertrophy\\:\\ 0\\.00576235624661848\ \(0\)\
\-\ tip\\:\\ 0\\.0057466600591391664\ \(0\)\
\-\ diffusely\\:\\ 0\\.005656236898605811\ \(0\)\
\-\ obvious\\:\\ 0\\.005656236898605811\ \(0\)\
\-\ scheduled\\:\\ 0\\.0056417548066181504\ \(0\)\
\-\ 2003\\:\\ 0\\.005627430992028123\ \(0\)\
\-\ angiography\\:\\ 0\\.005627430992028123\ \(0\)\
\-\ immediately\\:\\ 0\\.005558070046478526\ \(0\)\
\-\ definitive\\:\\ 0\\.0055313218529907055\ \(0\)\
\-\ entire\\:\\ 0\\.005505108659403983\ \(0\)\
\-\ consistent\\:\\ 0\\.00549226282786685\ \(0\)\
\-\ non\\-contrast\\:\\ 0\\.005466746428342236\ \(0\)\
\-\ contour\\:\\ 0\\.005429475215602348\ \(0\)\
\-\ upper\\:\\ 0\\.005405191364007126\ \(0\)\
\-\ larger\\:\\ 0\\.005393234676506005\ \(0\)\
\-\ catheter\\:\\ 0\\.00538137381737112\ \(0\)\
\-\ vessel\\:\\ 0\\.005334975485718543\ \(0\)\
\-\ c\\:\\ 0\\.005323628090249192\ \(0\)\
\-\ visible\\:\\ 0\\.005301223852556793\ \(0\)\
\-\ nature\\:\\ 0\\.005301223852556793\ \(0\)\
\-\ dense\\:\\ 0\\.0052901637363761056\ \(0\)\
\-\ appropriate\\:\\ 0\\.005279196174553673\ \(0\)\
\-\ phase\\:\\ 0\\.005268319630890901\ \(0\)\
\-\ embolization\\:\\ 0\\.00521525100526215\ \(0\)\
\-\ included\\:\\ 0\\.005164247838486693\ \(0\)\
\-\ small\\:\\ 0\\.005160092488548149\ \(0\)\
\-\ is\\:\\ 0\\.005158630994355281\ \(0\)\
\-\ decrease\\:\\ 0\\.005124827844728792\ \(0\)\
\-\ off\\:\\ 0\\.0051151553581001916\ \(0\)\
\-\ degenerative\\:\\ 0\\.0050771638287774494\ \(0\)\
\-\ present\\:\\ 0\\.005059000665613842\ \(0\)\
\-\ department\\:\\ 0\\.0050221648784510645\ \(0\)\
\-\ left\\:\\ 0\\.005012347414274782\ \(0\)\
\-\ there\\:\\ 0\\.005000192227254214\ \(0\)\
\-\ even\\:\\ 0\\.004986740668244092\ \(0\)\
\-\ circumscribed\\:\\ 0\\.004978032224313989\ \(0\)\
\-\ arterial\\:\\ 0\\.0049021554505015354\ \(0\)\
\-\ their\\:\\ 0\\.0049021554505015354\ \(0\)\
\-\ per\\:\\ 0\\.0049021554505015354\ \(0\)\
\-\ either\\:\\ 0\\.004877808942542249\ \(0\)\
\-\ do\\:\\ 0\\.004861825622628988\ \(0\)\
\-\ near\\:\\ 0\\.0048460348775226\ \(0\)\
\-\ had\\:\\ 0\\.0048331581107226955\ \(0\)\
\-\ aorta\\:\\ 0\\.0048073708350629685\ \(0\)\
\-\ dilatation\\:\\ 0\\.00479977303993279\ \(0\)\
\-\ on\\:\\ 0\\.004743715677361914\ \(0\)\
\-\ and\\/or\\:\\ 0\\.004733305028688994\ \(0\)\
\-\ procedure\\:\\ 0\\.004690794837662581\ \(0\)\
\-\ taken\\:\\ 0\\.004670045866212147\ \(0\)\
\-\ done\\:\\ 0\\.004642881868155637\ \(0\)\
\-\ non\\:\\ 0\\.004629508119565543\ \(0\)\
\-\ levels\\:\\ 0\\.004622872075061551\ \(0\)\
\-\ stable\\:\\ 0\\.004616269461654005\ \(0\)\
\-\ female\\:\\ 0\\.004604876203008738\ \(0\)\
\-\ increasing\\:\\ 0\\.0045901866905959515\ \(0\)\
\-\ 12\\:\\ 0\\.004583746304223174\ \(0\)\
\-\ appear\\:\\ 0\\.004583746304223174\ \(0\)\
\-\ upon\\:\\ 0\\.0045773374113081125\ \(0\)\
\-\ initially\\:\\ 0\\.00455829665041308\ \(0\)\
\-\ complications\\:\\ 0\\.004437972208403745\ \(0\)\
\-\ use\\:\\ 0\\.004426525707789388\ \(0\)\
\-\ subsequent\\:\\ 0\\.004359869852961745\ \(0\)\
\-\ images\\:\\ 0\\.004296890935647062\ \(0\)\
\-\ pattern\\:\\ 0\\.00428105155841583\ \(0\)\
\-\ of\\:\\ 0\\.004275368836623429\ \(0\)\
\-\ tumors\\:\\ 0\\.004206705580171037\ \(0\)\
\-\ has\\:\\ 0\\.00420629087940833\ \(0\)\
\-\ appears\\:\\ 0\\.004168714050848295\ \(0\)\
\-\ clear\\:\\ 0\\.004140926098488395\ \(0\)\
\-\ laboratory\\:\\ 0\\.004127249981460112\ \(0\)\
\-\ since\\:\\ 0\\.004113715100521909\ \(0\)\
\-\ early\\:\\ 0\\.004095883315389827\ \(0\)\
\-\ calcification\\:\\ 0\\.00406524982759781\ \(0\)\
\-\ vein\\:\\ 0\\.004052337250346157\ \(0\)\
\-\ being\\:\\ 0\\.0039027365357805484\ \(0\)\
\-\ elevated\\:\\ 0\\.0037998903818598465\ \(0\)\
\-\ masses\\:\\ 0\\.003785835384005357\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.003785835384005357\ \(0\)\
\-\ although\\:\\ 0\\.0037823450597334256\ \(0\)\
\-\ three\\:\\ 0\\.003775392173455977\ \(0\)\
\-\ initial\\:\\ 0\\.003711116832607219\ \(0\)\
\-\ spine\\:\\ 0\\.003688209103545672\ \(0\)\
\-\ radiation\\:\\ 0\\.003675296526294019\ \(0\)\
\-\ vascular\\:\\ 0\\.003672088162416378\ \(0\)\
\-\ showed\\:\\ 0\\.003672088162416378\ \(0\)\
\-\ area\\:\\ 0\\.0035410697826137186\ \(0\)\
\-\ resection\\:\\ 0\\.0034926810688338385\ \(0\)\
\-\ clinical\\:\\ 0\\.0034460154653551825\ \(0\)\
\-\ only\\:\\ 0\\.0033675120032567963\ \(0\)\
\-\ her\\:\\ 0\\.0033675120032567963\ \(0\)\
\-\ treated\\:\\ 0\\.0033523602045660017\ \(0\)\
\-\ from\\:\\ 0\\.003319621790705668\ \(0\)\
\-\ years\\:\\ 0\\.003288654176957382\ \(0\)\
\-\ infection\\:\\ 0\\.0032555918402002713\ \(0\)\
\-\ evaluation\\:\\ 0\\.003253261855605253\ \(0\)\
\-\ changes\\:\\ 0\\.0032097614367431987\ \(0\)\
\-\ region\\:\\ 0\\.003163304360733044\ \(0\)\
\-\ chronic\\:\\ 0\\.003154639099484928\ \(0\)\
\-\ scan\\:\\ 0\\.0031353492273040345\ \(0\)\
\-\ blood\\:\\ 0\\.003056895245752686\ \(0\)\
\-\ enhancement\\:\\ 0\\.003001951200685499\ \(0\)\
\-\ due\\:\\ 0\\.0029885676971858973\ \(0\)\
\-\ than\\:\\ 0\\.0029345332305613027\ \(0\)\
\-\ prior\\:\\ 0\\.0028756392820476584\ \(0\)\
\-\ both\\:\\ 0\\.002860026200112872\ \(0\)\
\-\ metastatic\\:\\ 0\\.002819278379575479\ \(0\)\
\-\ abdominal\\:\\ 0\\.002799369905795695\ \(0\)\
\-\ none\\:\\ 0\\.0027781382790406377\ \(0\)\
\-\ increased\\:\\ 0\\.002739822780864555\ \(0\)\
\-\ 3\\:\\ 0\\.002622510519929934\ \(0\)\
\-\ lower\\:\\ 0\\.0025188231577508028\ \(0\)\
\-\ it\\:\\ 0\\.0025174946062031674\ \(0\)\
\-\ year\\:\\ 0\\.002506173707137391\ \(0\)\
\-\ may\\:\\ 0\\.0024565247298795855\ \(0\)\
\-\ case\\:\\ 0\\.002450202402185152\ \(0\)\
\-\ demonstrates\\:\\ 0\\.0024464235932545033\ \(0\)\
\-\ have\\:\\ 0\\.0024252137331128333\ \(0\)\
\-\ 2\\:\\ 0\\.002411670375505303\ \(0\)\
\-\ and\\:\\ 0\\.0023592268116935577\ \(0\)\
\-\ multiple\\:\\ 0\\.0023588545261851493\ \(0\)\
\-\ surgical\\:\\ 0\\.0023541569728066235\ \(0\)\
\-\ after\\:\\ 0\\.002317170645621497\ \(0\)\
\-\ old\\:\\ 0\\.002293406544855189\ \(0\)\
\-\ treatment\\:\\ 0\\.002266863642989367\ \(0\)\
\-\ patient\\:\\ 0\\.002245326162297216\ \(0\)\
\-\ also\\:\\ 0\\.002207889375714484\ \(0\)\
\-\ within\\:\\ 0\\.0021364762888415223\ \(0\)\
\-\ which\\:\\ 0\\.002090622001628504\ \(0\)\
\-\ by\\:\\ 0\\.001864837356808486\ \(0\)\
\-\ disease\\:\\ 0\\.0018305865546732688\ \(0\)\
\-\ \\.\\:\\ 0\\.001721471606293332\ \(0\)\
\-\ are\\:\\ 0\\.001526702323105638\ \(0\)\
\-\ or\\:\\ 0\\.0013126117286549246\ \(0\)\
\-\ with\\:\\ 0\\.0009200852641406793\ \(0\)\
